Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9698278 | 0.84 | ENPP2 (0.38) | ALDH1A1KDM4EL3MBTL1KMT2AGSK3A | |
| SCHEMBL8912197 | 0.84 | KMT2A (0.45) | ALDH1A1KDM4EL3MBTL1KMT2APOLB | |
| SCHEMBL8912481 | 0.83 | KMT2A (0.40) | ALDH1A1KDM4EL3MBTL1KMT2AGSK3A | |
| SCHEMBL23772924 | 0.82 | TDP1 (0.42) | ALDH1A1KDM4EL3MBTL1KMT2AGSK3A | |
| SCHEMBL4085410 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4EL3MBTL1KMT2AGSK3A | |
| SCHEMBL4085412 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4EL3MBTL1KMT2AGSK3A | |
| SCHEMBL7458942 | 0.81 | ALDH1A1 (0.37) | ALDH1A1KDM4EMGAMGAASI | |
| SCHEMBL3645840 | 0.81 | GSK3A (0.45) | ALDH1A1KDM4EL3MBTL1KMT2AGSK3A | |
| Hydrochloric Acid SCHEMBL23751634 | 0.81 | TDP1 (0.41) | ALDH1A1KDM4EL3MBTL1KMT2AGSK3A | |
| SCHEMBL30028689 | 0.80 | MEN1 (0.43) | ALDH1A1KDM4EKMT2AGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110022865-A | METHODS OF MANAGING PAIN USING DEXMEDETOMIDINE TRANSDERMAL DELIVERY DEVICES | 帝国制药美国公司 | 2019-07-16 | — | — | CN | disclosed |
| EP-2702043-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | Exelixis, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20130345208-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8546414-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-01 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012149528-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | EXELIXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120270318-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-8258148-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767680-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100184753-A1 | Ion Channel Modulators and Methods of Uses | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| CN-101031296-A | Modulators of muscarinic receptors | VERTEX PHARMA (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-1809290-A2 | PYRIMIDINE DERIVATIVES AS ION CHANNEL MODULATORS AND METHODS OF USE | Vertex Pharmaceuticals Incorporated (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1781288-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060160817-A1 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-20 | — | — | US | disclosed |
| WO-2006050476-A2 | PYRIMIDINE DERIVATIVES AS ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060079505-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2006023852-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079505-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | ALDH1A1 2356/4885KDM4E 3396/4885L3MBTL1 3986/4885 |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | ALDH1A1 2356/4885KDM4E 3396/4885L3MBTL1 3986/4885 |
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM4 | ALDH1A1 1076/4885KDM4E 3385/4885L3MBTL1 4570/4885 |
| US-20060160817-A1 | Ion channel modulators and methods of use | CACNA1G, CACNA1C, CACNA1B | ALDH1A1 3619/4885KDM4E 2537/4885L3MBTL1 3492/4885 |
| US-20100184753-A1 | Ion Channel Modulators and Methods of Uses | CACNA1G, CACNA1C, CACNA1B | ALDH1A1 3514/4885KDM4E 2579/4885L3MBTL1 3470/4885 |
| US-20130345208-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1B, TRPV1, CACNA1C | ALDH1A1 2912/4885KDM4E 1402/4885L3MBTL1 3762/4885 |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | ALDH1A1 1353/4885KDM4E 3467/4885L3MBTL1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.